Investigational drug · Phase 2
RT023
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Advanced Malignant Solid Tumours.
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "RT023"
First trial start
2026
Sep 16, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "RT023", any sponsor or status.
Conditions studied
As listed on its trial records.
- Advanced Malignant Solid Tumours
Approved drugs for the same conditions: Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "RT023" as an intervention, largest first.
Shanghai Ruotuo Biosciences Co., Ltd.Industry
NCT07797426 · 318 participants (planned) · Start Sep 16, 2026 · Primary completion Jun 30, 2029
Drug: RT023 · For: Advanced Malignant Solid Tumours
Sites: Shanghai, China
Newest research
PubMed records naming it or its code names, newest first.
- Genome sequence of Clostridioides difficile PRB1128, a RT023 strain containing a mobile genetic element allowing for xylitol utilization.
Wozniak KJ, Corver J, Kuijper EJ, et al. · Microbiol Resour Announc 2026
- Acquisition of a gene cluster in Clostridioides difficile PCR ribotype 023 strains enables xylitol utilization.
Wozniak KJ, Pan L, Zhu D, et al. · mSphere 2026
- Distribution of Clostridioides difficile ribotypes and sequence types across humans, animals and food in 13 European countries.
Rupnik M, Viprey V, Janezic S, et al. · Emerg Microbes Infect 2024
- Discrimination between hypervirulent and non-hypervirulent ribotypes of Clostridioides difficile by MALDI-TOF mass spectrometry and machine learning.
Abdrabou AMM, Sy I, Bischoff M, et al. · Eur J Clin Microbiol Infect Dis 2023
- Clostridioides difficile from Fecally Contaminated Environmental Sources: Resistance and Genetic Relatedness from a Molecular Epidemiological Perspective.
Blau K, Berger FK, Mellmann A, et al. · Microorganisms 2023
- The Effect of Selected Bee Products on Adhesion and Biofilm of Clostridioides difficile Strains Belonging to Different Ribotypes.
Wultaska D, Paterczyk B, Nowakowska J, et al. · Molecules 2022
Also in development for Advanced Malignant Solid Tumours
- SCTB41Phase 36 trials
Sinocelltech Ltd. · NHL - Non-Hodgkin's Lymphoma, NSCLC (Advanced Non-small Cell Lung Cancer), Advanced Malignant Solid Tumor
- SCTB14Phase 32 trials
Sinocelltech Ltd. · Non-Small Cell Lung Carcinoma (NSCLC), Advanced Malignant Solid Tumours
- RT036Phase 21 trial
Shanghai Ruotuo Biosciences Co., Ltd. · Advanced Malignant Solid Tumours
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.